In early December 2025, the U.S. Food and Drug Administration (FDA) announced a nationwide recall of approximately 11,100 bottles of a widely used blood pressure medication, Ziac. This recall was initiated after laboratory testing confirmed the presence of ezetimibe, a cholesterol-lowering medication, in the reserve samples of the product. The potential contamination raised significant concerns about the safety of consumers who may have used these pills, prompting the FDA's action to prevent adverse health risks. The medication in question is a combination of bisoprolol fumarate and hydrochlorothiazide, which is frequently prescribed to help manage high blood pressure, also known as hypertension. Bisoprolol is a beta-blocker that aids in regulating heartbeat, while hydrochlorothiazide is a diuretic that promotes increased urination, helping to reduce excess sodium and water in the body. Together, these drugs work to lower blood pressure, subsequently lowering the risks of heart attacks and strokes. The recall was categorized as Class III, indicating that the likelihood of serious health consequences from exposure to the contaminated product is not significant. Affected dosages include 2.5-milligram and 6.25-milligram formulations, and specific impacted product codes involve 30-count, 100-count, and 500-count bottles, all linked to lot numbers with expiration dates spanning from November 2025 to May 2026. This extensive recall reflects the FDA's ongoing commitment to ensure drug safety and consumer protection amid concerns over medication contamination in the pharmaceutical industry. Manufactured by Glenmark Pharmaceuticals, based in Elmwood Park, New Jersey, both Ziac and ezetimibe are produced by the company. The FDA has yet to provide instructions on what consumers should do if they're in possession of the recalled medication, leaving many patients uncertain about their next steps as they manage their health. Such recalls highlight the importance of rigorous quality control measures and the essential role regulatory agencies play in safeguarding public health.